Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high‐risk aggressive non‐Hodgkin's lymphoma
暂无分享,去创建一个
A. Nagler | A. Shimoni | I. Hardan | P. Raanani | A. Avigdor | M. Yeshurun | I. Ben-bassat